AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22676398 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based aftercare program (individualized self-monitoring module and weekly 90-min chat sessions)
Number of subjects: 75
Study 22676398 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 75
Study 19401066 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI plus supportive care
Number of subjects: 220
Study 19401066 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 220
Study 17416108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 x 3 g/24 hours
Number of subjects: 30
Study 17416108 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime divided into 6 administrations of 2 x 3 g/24 hours
Number of subjects: 30
Study 17416108 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dosing regimen (1 g x 6 administrations)
Number of subjects: 30
Study 17416108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime clearance
Number of subjects: 30
Study 15021446 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene + low-dose, transdermal estrogen (RLX+E)
Number of subjects: 60
Study 15021446 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene + placebo (RLX+P)
Number of subjects: 60
Study 11403120 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 6 days
Number of subjects: 14
Study 11403120 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 34 days
Number of subjects: 14
Study 11403120 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 14
Study 9552032 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous radiotherapy plus chemotherapy (arm B)
Number of subjects: 270
Study 9552032 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 270
Study 7925193 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg succimer/kg body wt
Number of subjects: 12
Study 7925193 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg succimer/kg body wt
Number of subjects: 12
Study 7925193 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 3051392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary omega-3 fatty acids from fish and fish oil
Number of subjects: 68
Study 30246910 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient containing lactic acid and refined almond oil
Number of subjects: 0
Study 30246910 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient containing lactic acid, refined almond oil, and polidocanol
Number of subjects: 0
Study 28837002 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk consumption (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis Bb‐12, Lactobacillus acidophilus La‐5) during and after pregnancy
Number of subjects: 298
Study 24939868 — intervention group
Group type: EXPERIMENTAL
Intervention: Local sinusoidal extremely low frequency magnetic field (LSELF‐MF) exposure at 45 Hz-360 µT
Number of subjects: 24
Study 24939868 — intervention group
Group type: COMPARATOR
Intervention: Traditional neurofeedback (NF) without LSELF‐MF exposure
Number of subjects: 24
Study 24500553 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive exercise
Number of subjects: 0
Study 21156715 — intervention group
Group type: COMPARATOR
Intervention: Online educational training for VTE prophylaxis
Number of subjects: 67
Study 18802744 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 70
Study 18802744 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 70
Study 16958290 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 24
Study 16958290 — intervention group
Group type: EXPERIMENTAL
Intervention: everStick NET (glass fiber)
Number of subjects: 24
Study 16958290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond THM (polyethylene fiber)
Number of subjects: 24
Study 15193474 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural-cycle IVF
Number of subjects: 129
Study 15193474 — intervention group
Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation with microdose GnRH analog flare
Number of subjects: 129
Study 11509512 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐wk standard hospital rehabilitation program supplemented with an exercise training program (n = 19)
Number of subjects: 35
Study 11509512 — intervention group
Group type: COMPARATOR
Intervention: Home‐based rehabilitation program without exercise (n = 16)
Number of subjects: 35
Study 9678091 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Number of subjects: 56
Study 9678091 — intervention group
Group type: COMPARATOR
Intervention: Monophasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Number of subjects: 56
Study 8510082 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM 100 (Marshall F-88)
Number of subjects: 40
Study 8510082 — intervention group
Group type: COMPARATOR
Intervention: random zero sphygmomanometer
Number of subjects: 40
Study 8510082 — intervention group
Group type: COMPARATOR
Intervention: Finapres
Number of subjects: 40
Study 2961938 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 240
Study 2961938 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 240
Study 31637452 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis (12.5% THC)
Number of subjects: 91
Study 31637452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (<0.1% THC)
Number of subjects: 91
Study 29142143 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 2 g/day
Number of subjects: 240
Study 29142143 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 240
Study 28758692 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session intervention targeting perfectionism
Number of subjects: 212
Study 28758692 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 25698079 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood condition (CS+ with chocolate mousse intake)
Number of subjects: 0
Study 25698079 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood condition (CS+ with chocolate mousse intake)
Number of subjects: 0
Study 25698079 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood condition (CS- without chocolate mousse intake)
Number of subjects: 0
Study 23628696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control challenging condition (experimental)
Number of subjects: 33
Study 23628696 — intervention group
Group type: COMPARATOR
Intervention: Control condition (inhibitory control not challenged)
Number of subjects: 33
Study 19793768 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks in-hospital exercise training (6 x 15 min bicycle/day, 5 days/week) and a hypocaloric diet, followed by a 5 months ambulatory program (30 min ergometer/day, 5 days/week, plus 1 h group exercise/week)
Number of subjects: 23
Study 19793768 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks in-hospital exercise training and hypocaloric diet
Number of subjects: 23
Study 19793768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 18377250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks, targeted by functional imaging at approximately 50% of motor movement threshold.
Number of subjects: 24
Study 18377250 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation therapy without CS) for 6 weeks.
Number of subjects: 24
Study 18377250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks.
Number of subjects: 24
Study 16670135 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril once daily for 24 weeks
Number of subjects: 40
Study 16670135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14595183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg
Number of subjects: 71
Study 14595183 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1 mg
Number of subjects: 71
Study 10381288 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable angina pectoris patients
Number of subjects: 31
Study 8887699 — intervention group
Group type: EXPERIMENTAL
Intervention: DIET program (computer‐presented health education package)
Number of subjects: 54
Study 8887699 — intervention group
Group type: COMPARATOR
Intervention: Placebo computer‐based program
Number of subjects: 54
Study 2064881 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 2064881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6337558 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B radiation (six daily treatments of one minimal erythemal dose (MErD) prior to starting daily applications of a 0.02% mechlorethamine ointment and thereafter one MErD weekly)
Number of subjects: 0
Study 6337558 — intervention group
Group type: COMPARATOR
Intervention: Topical applications of mechlorethamine (0.02% ointment) without UV-B
Number of subjects: 0
Study 6337558 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B radiation
Number of subjects: 0
Study 31479007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training intervention (150 minutes of moderate intensity aerobic activity and two days of resistance training per week for 5 months)
Number of subjects: 0
Study 31479007 — intervention group
Group type: COMPARATOR
Intervention: Information only control group (monthly newsletters on type 2 diabetes education and prevention)
Number of subjects: 0
Study 29749323 — intervention group
Group type: EXPERIMENTAL
Intervention: δ-tocotrienol (300 mg twice daily)
Number of subjects: 71
Study 29749323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 27400468 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture dredging liver and regulating flow of theosophy (group 1)
Number of subjects: 163
Study 27400468 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint shallow stab (group 2)
Number of subjects: 163
Study 27400468 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint shallow stab (group 3)
Number of subjects: 163
Study 24524367 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNβ1a) 22 mcg subcutaneous injection three times per week
Number of subjects: 42
Study 24524367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22188162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid instrumentation technique
Number of subjects: 15
Study 22188162 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual instrumentation technique
Number of subjects: 15
Study 22188162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel-titanium (NiTi) rotary instrumentation technique
Number of subjects: 15
Study 22188162 — intervention group
Group type: COMPARATOR
Intervention: All techniques tested
Number of subjects: 15
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of sexual activity at preventive care visits
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of adolescents with high-risk behaviors
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of condoms
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of condoms
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom demonstrations
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for STI tests
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for HIV testing
Number of subjects: 468
Study 20308220 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to HIV and STI prevention counseling
Number of subjects: 468
Study 18173156 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture (EA) at Sishencong (EX‐HN 1)
Number of subjects: 276
Study 18173156 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Tianmeng Capsule (Control)
Number of subjects: 276
Study 15804995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ondansetron (5 mg/m2) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Number of subjects: 22
Study 15804995 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) ondansetron (4-8 mg according to body surface area) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Number of subjects: 22
Study 15804995 — intervention group
Group type: COMPARATOR
Intervention: IV ondansetron
Number of subjects: 22
Study 15804995 — intervention group
Group type: COMPARATOR
Intervention: ODT ondansetron
Number of subjects: 22
Study 12020139 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (specific mobilization techniques)
Number of subjects: 183
Study 12020139 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (exercise therapy)
Number of subjects: 183
Study 12020139 — intervention group
Group type: COMPARATOR
Intervention: Continued care by a general practitioner (analgesics, counseling, and education)
Number of subjects: 183
Study 10776091 — intervention group
Group type: EXPERIMENTAL
Intervention: Venepuncture
Number of subjects: 36
Study 10776091 — intervention group
Group type: COMPARATOR
Intervention: Heel prick
Number of subjects: 36
Study 8551733 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ACMF (6 cycles): 130 mg/m2 CPA, 26 mg/m2 MTX, 600 mg/m2 5-FU, 26 mg/m2 ADM
Number of subjects: 190
Study 8551733 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ACMF (12 cycles): 65 mg/m2 CPA, 13 mg/m2 MTX, 300 mg/m2 5-FU, 13 mg/m2 ADM
Number of subjects: 190
Study 2112243 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐penicillamine 10‐12 mg/day
Number of subjects: 103
Study 2112243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate 50 mg intramuscularly weekly
Number of subjects: 103
Study 2112243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oral methotrexate 7.5‐15.0 mg weekly
Number of subjects: 103
Study 2112243 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal rates due to adverse drug reactions
Number of subjects: 103
Study 389419 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 14
Study 389419 — intervention group
Group type: COMPARATOR
Intervention: Placebo normal saline (S) infusion
Number of subjects: 14
Study 31434498 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment combined with fisetin
Number of subjects: 0
Study 31434498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28229937 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐atDCS over the left and right M1 (STIM, n = 16)
Number of subjects: 31
Study 28229937 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (SHAM, n = 15)
Number of subjects: 31
Study 27177436 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSB)
Number of subjects: 59
Study 27177436 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 59
Study 24969577 — intervention group
Group type: EXPERIMENTAL
Intervention: glimepiride
Number of subjects: 40
Study 24969577 — intervention group
Group type: COMPARATOR
Intervention: exenatide
Number of subjects: 40
Study 24969577 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 40
Study 22099425 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/d, n 46)
Number of subjects: 96
Study 22099425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n 50)
Number of subjects: 96
Study 19007835 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (Priorix-Tetra)
Number of subjects: 458
Study 19007835 — intervention group
Group type: COMPARATOR
Intervention: MMR+V (Priorix and Varilrix)
Number of subjects: 458
Study 17967669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 50 mg mixed with 8.4% NaHCO(3) 3 mL
Number of subjects: 180
Study 17967669 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium only
Number of subjects: 180
Study 17967669 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 50 mg mixed with 0.9% NaCl 3 mL
Number of subjects: 180
Study 16612275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 16612275 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 0
Study 11889777 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 25 ng.kg‐1.min‐1
Number of subjects: 30
Study 11889777 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 50 ng.kg‐1.min‐1
Number of subjects: 30
Study 10439741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hematocrit (aiming for 20%)
Number of subjects: 35
Study 10439741 — intervention group
Group type: COMPARATOR
Intervention: High hematocrit (aiming for 30%)
Number of subjects: 35
Study 8903921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20‐30 mg/day)
Number of subjects: 38
Study 8903921 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 asymptomatic postmenopausal women)
Number of subjects: 38
Study 8903921 — intervention group
Group type: COMPARATOR
Intervention: No-tamoxifen group (25 asymptomatic postmenopausal breast cancer patients)
Number of subjects: 38
Study 2699011 — intervention group
Group type: COMPARATOR
Intervention: Classical anaesthesia with benzodiazepine‐analgesic (diazepam and fentanyl)
Number of subjects: 45
Study 2699011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia variant with flunitrazepam and buprenorphine
Number of subjects: 45
Study 1258812 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking suggestion
Number of subjects: 7
Study 1258812 — intervention group
Group type: COMPARATOR
Intervention: Hypnosis
Number of subjects: 7
Study 1258812 — intervention group
Group type: COMPARATOR
Intervention: Posthypnotic suggestion
Number of subjects: 7
Study 31961196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 0
Study 31961196 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 30004255 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) users
Number of subjects: 112
Study 30004255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 27056250 — intervention group
Group type: EXPERIMENTAL
Intervention: Gloreha hand rehabilitation glove
Number of subjects: 30
Study 27056250 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand rehabilitation
Number of subjects: 30
Study 25893536 — intervention group
Group type: EXPERIMENTAL
Intervention: High power
Number of subjects: 0
Study 25893536 — intervention group
Group type: COMPARATOR
Intervention: Low power
Number of subjects: 0
Study 23485954 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated assessments with the Montgomery‐Åsberg Depression Rating Scale (MADRS) and the self‐rating version (MADRS‐S) at baseline and week 2.
Number of subjects: 400
Study 23485954 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors at baseline and week 2 used for prediction modeling.
Number of subjects: 400
Study 21965767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin scale
Number of subjects: 114
Study 21965767 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI-CTC sensory scale
Number of subjects: 114
Study 18077657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print materials accompanied by personalized dietary counseling via lay health advisors (promotoras)
Number of subjects: 357
Study 18077657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print materials
Number of subjects: 357
Study 18077657 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Spanish language targeted materials)
Number of subjects: 357
Study 16323382 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (2.0‐4.4 Hz oscillations at 3‐mm amplitude)
Number of subjects: 12
Study 16323382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Burst‐transcutaneous electrical nerve stimulation on the nondominant forearm)
Number of subjects: 12
Study 16323382 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 12
Study 10334388 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (19 patients whose Hb values improved after infection)
Number of subjects: 48
Study 10334388 — intervention group
Group type: COMPARATOR
Intervention: Group II (10 patients with persisting anemia after infection)
Number of subjects: 48
Study 10334388 — intervention group
Group type: COMPARATOR
Intervention: Group III (8 patients without hepatitis virus markers with Hb > 85 g/L)
Number of subjects: 48
Study 10334388 — intervention group
Group type: COMPARATOR
Intervention: Group IV (11 patients without hepatitis virus markers with Hb < 75 g/L)
Number of subjects: 48
Study 10334388 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 48
Study 7492041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy in the Gamow bag at 1.58 atmospheres absolute pressure (8.5 psi) for 40 minutes
Number of subjects: 12
Study 7492041 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen through a nonrebreather mask at 15 L/minute for 40 minutes
Number of subjects: 12
Study 1827105 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (2 x 125 mg capsules, 12-hourly)
Number of subjects: 128
Study 1827105 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK (2 x 125 mg tablets, 6-hourly)
Number of subjects: 128
Study 1827105 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 128
Study 1827105 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK
Number of subjects: 128
Study 6796269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with mannitol diuresis
Number of subjects: 67
Study 6796269 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin without mannitol diuresis
Number of subjects: 67